nach oben

Inflammation

Erschienen in:

18.06.2021 | Original Article

Schisandrin B Attenuates Airway Inflammation and Airway Remodeling in Asthma by Inhibiting NLRP3 Inflammasome Activation and Reducing Pyroptosis

verfasst von: Xiufeng Chen, Zhen Xiao, Zhiyan Jiang, Yonghong Jiang, Wen Li, Mingjing Wang

Erschienen in: Inflammation | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Asthma is a chronic inflammatory disorder of the airways. Schisandrin B (SB) is the main effective component. This study investigated the effects of SB on airway inflammation and airway remodeling in asthma. The rat model of asthma was established. The rats were treated with SB to evaluate the effects of SB on airway inflammation, airway remodeling, NLRP3 inflammasome activation, and pyroptosis. Alveolar macrophages of rats were isolated, and the macrophage inflammatory model was established by lipopolysaccharide (LPS) induction. The LPS-induced macrophages were treated with SB. The binding relationship between miR-135a-5p and TPRC1 was analyzed. LPS + SB-treated macrophages were transfected with miR-135a-5p inhibitor. The expressions of key factors of the STAT3/NF-κB pathway were detected. SB reduced airway inflammation and airway remodeling in asthmatic rats. SB inhibited NLRP3 inflammasome activation and reduced pyroptosis in asthmatic rats and LPS-induced macrophages. SB reversely regulated the miR-135a-5p/TRPC1 axis. Downregulation of miR-135a-5p attenuated the inhibitory effect of SB on NLRP3 inflammasome activation. SB inhibited the STAT3/NF-κB pathway via the miR-135a-5p/TRPC1 axis. In conclusion, SB inhibited NLRP3 inflammasome activation and reduced pyroptosis via the miR-135a-5p/TRPC1/STAT3/NF-κB axis, thus alleviating airway inflammation and airway remodeling in asthma. This study may confer novel insights for the management of asthma.

Radhakrishna, N., T.R. Tay, F. Hore-Lacy, R. Hoy, E. Dabscheck, and M. Hew. 2016. Profile of difficult to treat asthma patients referred for systematic assessment. Respir Med 117: 166–173.PubMedCrossRef

Bousquet, J., E. Mantzouranis, A.A. Cruz, N. Ait-Khaled, et al. 2010. Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 126 (5): 926–938.PubMedCrossRef

Akinbami, L.J., J.E. Moorman, A.E. Simon, and K.C. Schoendorf. 2014. Trends in racial disparities for asthma outcomes among children 0 to 17 years, 2001-2010. J Allergy Clin Immunol 134 (3): 547–553 e545.PubMedPubMedCentralCrossRef

Alhassan, S., Y. Hattab, O. Bajwa, E. Bihler, and A.C. Singh. 2016. Asthma. Crit Care Nurs Q 39 (2): 110–123.PubMedCrossRef

Fergeson, J.E., S.S. Patel, and R.F. Lockey. 2017. Acute asthma, prognosis, and treatment. J Allergy Clin Immunol 139 (2): 438–447.PubMedCrossRef

Mims, J.W. 2015. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol 5 (Suppl 1): S2–S6.PubMedCrossRef

Papi, A., C. Brightling, S.E. Pedersen, and H.K. Reddel. 2018. Asthma. Lancet 391 (10122): 783–800.PubMedCrossRef

Castillo, J.R., S.P. Peters, and W.W. Busse. 2017. Asthma exacerbations: Pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract 5 (4): 918–927.PubMedPubMedCentralCrossRef

Boulet, L.P. 2018. Airway remodeling in asthma: Update on mechanisms and therapeutic approaches. Curr Opin Pulm Med 24 (1): 56–62.PubMedCrossRef

10.

Liu, G., M.A. Cooley, P.M. Nair, C. Donovan, A.C. Hsu, A.G. Jarnicki, T.J. Haw, N.G. Hansbro, Q. Ge, A.C. Brown, H. Tay, P.S. Foster, P.A. Wark, J.C. Horvat, J.E. Bourke, C.L. Grainge, W.S. Argraves, B.G. Oliver, D.A. Knight, J.K. Burgess, and P.M. Hansbro. 2017. Airway remodelling and inflammation in asthma are dependent on the extracellular matrix protein fibulin-1c. J Pathol 243 (4): 510–523.PubMedCrossRef

11.

Al-Muhsen, S., J.R. Johnson, and Q. Hamid. 2011. Remodeling in asthma. J Allergy Clin Immunol 128 (3): 451–462 quiz 463-454.PubMedCrossRef

12.

Du, H., Y. Wang, Y. Shi, J. Yu, W. Sun, and Y. Zhang. 2016. Effect of traditional Chinese medicine on inflammatory mediators in pediatric asthma. Mediat Inflamm 2016: 5143703.CrossRef

13.

Rybnikar, M., K. Smejkal, and M. Zemlicka. 2019. Schisandra chinensis and its phytotherapeutical applications. Ceska Slov Farm 68 (3): 95–118.PubMed

14.

Nasser, M.I., S. Zhu, C. Chen, M. Zhao, H. Huang, and P. Zhu. 2020. A Comprehensive review on Schisandrin B and its biological properties. Oxidative Med Cell Longev 2020: 2172740.CrossRef

15.

Leong, P.K., and K.M. Ko. 2016. Schisandrin B: A double-edged sword in nonalcoholic fatty liver disease. Oxidative Med Cell Longev 2016: 6171658.CrossRef

16.

Ji, Z.R., W.L. Xue, and L. Zhang. 2019. Schisandrin B attenuates inflammation in LPS-induced sepsis through miR-17-5p downregulating TLR4. Inflammation 42 (2): 731–739.PubMedCrossRef

17.

Mou, Z., Z. Feng, Z. Xu, F. Zhuang, X. Zheng, X. Li, J. Qian, and G. Liang. 2019. Schisandrin B alleviates diabetic nephropathy through suppressing excessive inflammation and oxidative stress. Biochem Biophys Res Commun 508 (1): 243–249.PubMedCrossRef

18.

Zhang, X.Y., L.X. Zhang, Y.L. Guo, L.M. Zhao, X.Y. Tang, C.J. Tian, D.J. Cheng, X.L. Chen, L.J. Ma, and Z.C. Chen. 2016. Schisandrin B inhibits the proliferation of airway smooth muscle cells via microRNA-135a suppressing the expression of transient receptor potential channel 1. Cell Biol Int 40 (7): 742–749.PubMedCrossRef

19.

Zhang, X.Y., X.Y. Tang, L.J. Ma, Y.L. Guo, X.S. Li, L.M. Zhao, C.J. Tian, D.J. Cheng, Z.C. Chen, and L.X. Zhang. 2017. Schisandrin B down-regulated lncRNA BCYRN1 expression of airway smooth muscle cells by improving miR-150 expression to inhibit the proliferation and migration of ASMC in asthmatic rats. Cell Prolif 50 (6): e12382.PubMedCentralCrossRef

20.

Agarwal, V., G.W. Bell, J.W. Nam, and D.P. Bartel. 2015. Predicting effective microRNA target sites in mammalian mRNAs. Elife 4.

21.

Maslan, J., and J.W. Mims. 2014. What is asthma? Pathophysiology, demographics, and health care costs. Otolaryngol Clin N Am 47 (1): 13–22.CrossRef

22.

Bergeron, C., and L.P. Boulet. 2006. Structural changes in airway diseases: Characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 129 (4): 1068–1087.PubMedCrossRef

23.

Lee, M.Y., C.S. Seo, N.H. Lee, H. Ha, J.A. Lee, H. Lee, K.Y. Lee, and H.K. Shin. 2010. Anti-asthmatic effect of schizandrin on OVA-induced airway inflammation in a murine asthma model. Int Immunopharmacol 10 (11): 1374–1379.PubMedCrossRef

24.

Lee, K.S., S.J. Park, S.R. Kim, K.H. Min, K.Y. Lee, Y.H. Choe, S.H. Hong, Y.R. Lee, J.S. Kim, S.J. Hong, and Y.C. Lee. 2008. Inhibition of VEGF blocks TGF-beta1 production through a PI3K/Akt signalling pathway. Eur Respir J 31 (3): 523–531.PubMedCrossRef

25.

Wang, L., B. Zha, Q. Shen, H. Zou, C. Cheng, H. Wu, and R. Liu. 2018. Sevoflurane inhibits the Th2 response and NLRP3 expression in murine allergic airway inflammation. J Immunol Res 2018: 9021037.PubMedPubMedCentralCrossRef

26.

Cheng, Y., S. Li, M. Wang, C. Cheng, and R. Liu. 2018. Peroxisome proliferator activated receptor gamma (PPARgamma) agonist rosiglitazone ameliorate airway inflammation by inhibiting toll-like receptor 2 (TLR2)/Nod-like receptor with pyrin domain containing 3 (NLRP3) inflammatory corpuscle activation in asthmatic mice. Med Sci Monit 24: 9045–9053.PubMedPubMedCentralCrossRef

27.

Jorgensen, I., M. Rayamajhi, and E.A. Miao. 2017. Programmed cell death as a defence against infection. Nat Rev Immunol 17 (3): 151–164.PubMedPubMedCentralCrossRef

28.

He, W.T., H. Wan, L. Hu, P. Chen, X. Wang, Z. Huang, Z.H. Yang, C.Q. Zhong, and J. Han. 2015. Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion. Cell Res 25 (12): 1285–1298.PubMedPubMedCentralCrossRef

29.

Zhuang, J., H. Cui, L. Zhuang, Z. Zhai, F. Yang, G. Luo, J. He, H. Zhao, W. Zhao, Y. He, and E. Sun. 2020. Bronchial epithelial pyroptosis promotes airway inflammation in a murine model of toluene diisocyanate-induced asthma. Biomed Pharmacother 125: 109925.PubMedCrossRef

30.

Murray, P.J., and T.A. Wynn. 2011. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11 (11): 723–737.PubMedPubMedCentralCrossRef

31.

Lamkanfi, M., and V.M. Dixit. 2014. Mechanisms and functions of inflammasomes. Cell 157 (5): 1013–1022.PubMedCrossRef

32.

Pu, Q., Y. Zhao, Y. Sun, T. Huang, P. Lin, C. Zhou, S. Qin, B.B. Singh, and M. Wu. 2019. TRPC1 intensifies house dust mite-induced airway remodeling by facilitating epithelial-to-mesenchymal transition and STAT3/NF-kappaB signaling. FASEB J 33 (1): 1074–1085.PubMedCrossRef

33.

Sui, Y., L. Bian, Q. Ai, Y. Yao, M. Yu, H. Gao, A. Zhang, X. Fu, L. Zhong, and D. Lu. 2019. Gastrodin inhibits inflammasome through the STAT3 signal pathways in TNA2 astrocytes and reactive astrocytes in experimentally induced cerebral ischemia in rats. NeuroMolecular Med 21 (3): 275–286.PubMedCrossRef

34.

Jones, T.L., D.M. Neville, and A.J. Chauhan. 2018. Diagnosis and treatment of severe asthma: A phenotype-based approach. Clin Med (Lond) 18 (Suppl 2): s36–s40.CrossRef

35.

Zhang, H.P., L. Wang, Z. Wang, X.R. Xu, X.M. Zhou, G. Liu, L.Y. He, J. Wang, A. Hsu, W.M. Li, and G. Wang. 2018. Chinese herbal medicine formula for acute asthma: A multi-center, randomized, double-blind, proof-of-concept trial. Respir Med 140: 42–49.PubMedCrossRef

36.

Wang, M.H., C. Chen, M.L. Yeh, and J.G. Lin. 2019. Using traditional Chinese medicine to relieve asthma symptoms: A systematic review and meta-analysis. Am J Chin Med 47 (8): 1659–1674.PubMedCrossRef

37.

Shergis, J.L., L. Wu, A.L. Zhang, X. Guo, C. Lu, and C.C. Xue. 2016. Herbal medicine for adults with asthma: A systematic review. J Asthma 53 (6): 650–659.PubMedCrossRef

38.

Harrison, B.C., M.L. Bell, D.L. Allen, W.C. Byrnes, and L.A. Leinwand. 2002. Skeletal muscle adaptations in response to voluntary wheel running in myosin heavy chain null mice. J Appl Physiol (1985) 92 (1): 313–322.CrossRef

39.

Hirota, N., and J.G. Martin. 2013. Mechanisms of airway remodeling. Chest 144 (3): 1026–1032.PubMedCrossRef

40.

Vanaja, S.K., V.A. Rathinam, and K.A. Fitzgerald. 2015. Mechanisms of inflammasome activation: recent advances and novel insights. Trends Cell Biol 25 (5): 308–315.PubMedPubMedCentralCrossRef

41.

Schroder, K., and J. Tschopp. 2010. The inflammasomes. Cell 140 (6): 821–832.PubMedCrossRef

42.

Theofani, E., M. Semitekolou, I. Morianos, K. Samitas, and G. Xanthou. 2019. Targeting NLRP3 inflammasome activation in severe asthma. J Clin Med 8 (10).

43.

Shi, J., Y. Zhao, K. Wang, X. Shi, Y. Wang, H. Huang, Y. Zhuang, T. Cai, F. Wang, and F. Shao. 2015. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526 (7575): 660–665.PubMedCrossRef

44.

Ding, J., and F. Shao. 2017. SnapShot: The noncanonical inflammasome. Cell 168 (3): 544–544 e541.PubMedCrossRef

45.

Pinkerton, J.W., R.Y. Kim, A.A.B. Robertson, J.A. Hirota, L.G. Wood, D.A. Knight, M.A. Cooper, L.A.J. O'Neill, J.C. Horvat, and P.M. Hansbro. 2017. Inflammasomes in the lung. Mol Immunol 86: 44–55.PubMedCrossRef

46.

Gao, J., S. Peng, X. Shan, G. Deng, L. Shen, J. Sun, C. Jiang, X. Yang, Z. Chang, X. Sun, F. Feng, L. Kong, Y. Gu, W. Guo, Q. Xu, and Y. Sun. 2019. Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis. Cell Death Dis 10 (12): 957.PubMedPubMedCentralCrossRef

47.

Cheng, K.T., S. Xiong, Z. Ye, Z. Hong, A. di, K.M. Tsang, X. Gao, S. An, M. Mittal, S.M. Vogel, E.A. Miao, J. Rehman, and A.B. Malik. 2017. Caspase-11-mediated endothelial pyroptosis underlies endotoxemia-induced lung injury. J Clin Invest 127 (11): 4124–4135.PubMedPubMedCentralCrossRef

48.

Lamkanfi, M. 2011. Emerging inflammasome effector mechanisms. Nat Rev Immunol 11 (3): 213–220.PubMedCrossRef

49.

Kim, S.R., D.I. Kim, S.H. Kim, H. Lee, K.S. Lee, S.H. Cho, and Y.C. Lee. 2014. NLRP3 inflammasome activation by mitochondrial ROS in bronchial epithelial cells is required for allergic inflammation. Cell Death Dis 5: e1498.PubMedPubMedCentralCrossRef

50.

Guo, M., F. An, H. Yu, X. Wei, M. Hong, and Y. Lu. 2017. Comparative effects of schisandrin A, B, and C on Propionibacterium acnes-induced, NLRP3 inflammasome activation-mediated IL-1beta secretion and pyroptosis. Biomed Pharmacother 96: 129–136.PubMedCrossRef

51.

Herbert, C., M. Sebesfi, Q.X. Zeng, B.G. Oliver, P.S. Foster, and R.K. Kumar. 2015. Using multiple online databases to help identify microRNAs regulating the airway epithelial cell response to a virus-like stimulus. Respirology 20 (8): 1206–1212.PubMedCrossRef

52.

Li, N., Y. He, and M.C. Li. 2015. Role of transient receptor potential canonical 1 in airway remodeling and effect of budesonide on its pulmonary expression in asthmatic guinea pigs. Nan Fang Yi Ke Da Xue Xue Bao 35 (10): 1374–1379.PubMed

53.

Li, N., Y. He, G. Yang, Q. Yu, and M. Li. 2019. Role of TRPC1 channels in pressure-mediated activation of airway remodeling. Respir Res 20 (1): 91.PubMedPubMedCentralCrossRef

54.

Chang, J., J. Gao, L. Lou, H. Chu, P. Li, T. Chen, and F. Gao. 2020. Xanthatin alleviates airway inflammation in asthmatic mice by regulating the STAT3/NF-kappaB signaling pathway. Respir Physiol Neurobiol 281: 103491.PubMedCrossRef

Titel: Schisandrin B Attenuates Airway Inflammation and Airway Remodeling in Asthma by Inhibiting NLRP3 Inflammasome Activation and Reducing Pyroptosis
verfasst von: Xiufeng Chen
Zhen Xiao
Zhiyan Jiang
Yonghong Jiang
Wen Li
Mingjing Wang
Publikationsdatum: 18.06.2021
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 6/2021
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-021-01494-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Schisandrin B Attenuates Airway Inflammation and Airway Remodeling in Asthma by Inhibiting NLRP3 Inflammasome Activation and Reducing Pyroptosis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

The miR-223-3p Regulates Pyroptosis Through NLRP3-Caspase 1-GSDMD Signal Axis in Periodontitis

Immunotherapy-on-Chip Against an Experimental Sepsis Model

Correction To: Aspergillus fumigatus-Stimulated Human Corneal Epithelial Cells Induce Pyroptosis of THP-1 Macrophages by Secreting TSLP

Glutamine Supplementation Attenuates the Inflammation Caused by LPS-Induced Acute Lung Injury in Mice by Regulating the TLR4/MAPK Signaling Pathway

Blocking SphK1/S1P/S1PR1 Signaling Pathway Alleviates Lung Injury Caused by Sepsis in Acute Ethanol Intoxication Mice

CTRP-3 Regulates NOD1-mediated Inflammation and NOD1 Expression in Adipocytes and Adipose Tissue

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin